2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $1.8B | $1.6B | $1.7B | $1.7B | $1.7B |
Cost of Revenue | $1.5B | $1.4B | $1.5B | $1.5B | $1.5B |
Gross Profit | $268M | $227M | $194M | $215M | $228M |
Gross Profit % | 15% | 14% | 11% | 13% | 13% |
R&D Expenses | $0 | $0 | $0 | $0 | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | $99M | $46M | $35M | $38M | $39M |
Dep. & Amort. | $14M | $15M | $15M | $14M | $15M |
Def. Tax | -$5.9M | $3.1M | $5M | -$4.8M | -$2.9M |
Stock Comp. | $7.9M | $8.8M | $9.2M | $9M | $9.2M |
Chg. in WC | $99M | -$43M | -$115M | -$44M | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $139M | $71M | $26M | $54M | $57M |
ST Investments | $125M | $114M | $95M | $93M | $51M |
Cash & ST Inv. | $264M | $185M | $121M | $147M | $107M |
Receivables | $255M | $293M | $337M | $384M | $382M |
Inventory | $32M | $26M | $21M | $18M | $17M |
Q1 2025 revenue was $447.7M, up 5.7% YoY; net income was $17.2M ($0.23 EPS); cash flow from operations (ex-payroll accrual) was $32.1M, up $41.3M YoY.
Q2 2025 revenue is guided to $445M–$455M; second half revenue expected to grow sequentially over the first half; 2025 cash flow from operations guidance (ex-payroll accrual) raised to $60M–$75M (from $45M–$60M).
Cost of services was $379.7M (84.8% of revenue); 2025 goal is to manage cost of services in the 86% range; SG&A expected at 9.5%–10.5% near-term, with a longer-term target of 8.5%–9.5%.
Industry fundamentals are strong with positive demographic trends, stable reimbursement, and improved workforce availability; recent court ruling eliminated key provisions of the CMS minimum staffing rule, reducing regulatory overhang.
Balance sheet remains strong with $143.9M in cash/marketable securities and an undrawn $500M credit facility; DSO improved to 78 days (from 88); company made a small tuck-in acquisition (~1% revenue impact for 2025) and repurchased $7M in stock in Q1, with further buybacks expected.